Drug intelligence / Profile preview

SNG300

Development stage: Preclinical
Lead developer: Seanergy Dermatology
Modality: Small Molecules
Administration: Topical

Overview

**SNG300** is a Seanergy topical therapeutic candidate for **severe atopic dermatitis**. It is described as a co-formulated combination of algae-derived sulphated polysaccharides and an unspecified anti-inflammatory active pharmaceutical ingredient. Seanergy's platform is based on the reported synergistic enhancement of anti-inflammatory activity by sulphated polysaccharides, with the objective of improving topical efficacy while reducing treatment-related side effects. Specific active ingredients, molecular targets, formulation type, and clinical phase have not been publicly disclosed. ([seanergypharma.com](https://seanergypharma.com/))

Other names: SNG 300SNG300SNG-300

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SNG300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNG300.

Explore the full profile